Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.71 |
| ▸ | CCKBR | P32239 | 5/20 | 0.51 |
| ▸ | CCKAR | P32238 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653231 | 0.93 | PTGER4 (0.66) | PTGER4CCKBRCCKARHDAC1HDAC6 | |
| SCHEMBL5656713 | 0.86 | PTGER4 (0.77) | PTGER4CCKBRHDAC1HDAC6 | |
| SCHEMBL5655295 | 0.85 | PTGER4 (0.54) | PTGER4SIRT5 | |
| SCHEMBL27676042 | 0.85 | PTGER4 (0.54) | PTGER4SIRT5 | |
| SCHEMBL5653674 | 0.84 | PTGER4 (0.68) | PTGER4CCKBRCCKARHDAC1HDAC6 | |
| SCHEMBL5748518 | 0.84 | PTGER4 (0.68) | PTGER4CCKBRCCKARHDAC1HDAC6 | |
| SCHEMBL5653672 | 0.84 | PTGER4 (0.68) | PTGER4CCKBRCCKARHDAC1HDAC6 | |
| SCHEMBL5653761 | 0.84 | PTGER4 (0.74) | PTGER4HDAC1SIRT5 | |
| SCHEMBL5655465 | 0.83 | PTGER4 (0.52) | PTGER4HDAC1HDAC6SIRT5 | |
| SCHEMBL5656217 | 0.83 | PTGER4 (0.66) | PTGER4CCKBRCCKARHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | claimed |
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1697337-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061475-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | PTGER4 1/4885CCKBR 469/4885CCKAR 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.